Clinical Trial

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 21, 2021 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to further observe and evaluate whether the three-week administration of albumin-bound paclitaxel combined with gemcitabine is equivalent to the four-week administration in the treatment of inoperable locally advanced or metastatic pancreatic cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-08-31.
Trial Details
NCT Number NCT05035147
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Pancreatic Cancer
Enrollment 934 participants
Start Date 2021-03-25
Primary Completion 2026-04 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2021-09-21